Allergy Therapeutics Plc Investment driving market share gains

Hardman & Co ReportAllergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named Patient’ basis. Trials to obtain full regulatory approval as a biological have progressed well in the EU, and are back on-track in the US with a planned new safety trial. AGY remains on course to have the first short-course allergy vaccine approved in both Europe and the US. Meanwhile, an excellent trading performance in 1H’17 shows that AGY is continuing to gain market share from its international peers.

 

 

Trading update: Sales in the six months to December 2016 were over £2m ahead of market expectations, with exceptional underlying growth of +18% to £40.4m (£29.0m). Weakness in sterling boosted the reported numbers by about £6.0m. This strong performance has continued into the second half.

Net cash: At 31st December 2016, AGY had a cash balance of £27.8m, up from £23.4m at 30th June, and ca.£3.0m above forecasts. Assuming that debt has not changed significantly, net cash was £23.3m at the end of the period from £18.9m at 30th June, showing the cash generation from traditionally strong 1H trading.

Regulatory update: Management has made important progress with the FDA and a revised programme of trials to get Grass MATA MPL approved in the US has been agreed in principle, with part of this being conducted in Europe. Meanwhile, the final trial for the EU submission is set to start in 3Q 2017.

Changes to forecasts: Following the strong first half sales performance, we have increased our underlying sales growth expectation from +11.5% to +13%, which is still conservative and implies only +2% growth for 2H’17. Coupled to this we have corrected for forex, which adds £7.5m to reported sales numbers.

Investment summary: Allergy Therapeutics Plc has reported another exceptional underlying sales performance in 1H’17 against a flat market, giving significant market share gains in some countries. It has also made considerable progress towards US regulatory approval with a revised trial programme. Despite this, the shares still trade stubbornly below those of international peers that are losing market share and do not have access to the new short-course immunotherapy (SCIT) technology.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Hardman & Co

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million